NUP98 and acute myeloid leukemia: Despite the fact that our study was partly based on data collected prospectively since 2004 and partly on data assessed de novo on stored material by either NGS or PCR, we can safely conclude that co-occurrence of the three factors, mutated WT1 and FLT3-ITD and/or NUP98-NSD1 translocation, still defines a subgroup of AML patients with devastating EFS and OS outcome, even with our current treatment protocols.